Ipamorelin Side Effects: What the Evidence Shows and Who Should Avoid It

9 min readWritten by Protocol Health Editorial TeamMedically reviewed by Richard Dentico, MDPublished Updated

Ipamorelin side effects are poorly studied: the only controlled human trial gave it intravenously to hospital patients for up to seven days. Here is what it found, which risks are borrowed from related drugs and what the FDA says.

Ipamorelin Side Effects: What the Evidence Shows and Who Should Avoid It
Here’s what we’ll cover

Key takeaways

  • The side effects of ipamorelin are poorly mapped, because the only controlled human trial gave it intravenously to hospital patients for up to seven days.
  • Ipamorelin side effects in clinical studies come from two small human studies, both of intravenous ipamorelin, and neither tested the uses it is marketed for today.
  • Ipamorelin side effects compared to GHRP-2 and GHRP-6 look milder on the hormone side, but that comparison was made in animals, not people.
  • Ipamorelin may cause water retention, because raising growth hormone tends to make the body hold fluid, but no study has measured water retention in people taking ipamorelin itself.
  • Ipamorelin side effects on hunger and blood sugar are expected from its target, because ipamorelin acts on the ghrelin receptor, the receptor the body's hunger hormone uses.

Short Answer

What Are the Side Effects of Ipamorelin?

The side effects of ipamorelin are poorly mapped, because the only controlled human trial gave it intravenously to hospital patients for up to seven days. Most of what clinicians watch for, such as hunger, fluid retention, joint aches and higher blood sugar, is borrowed from related drugs.

Protocol Health prescribes compounded ipamorelin after a physician evaluation, so we have a commercial interest in this topic, and this page puts the risks first for that reason. Ipamorelin is not FDA-approved for any use.

Possible side effectMeasured in people taking ipamorelin?Where the signal comes from
Hunger or increased appetiteNo published dataMK-677 trial; macimorelin label
Water retention, swelling, joint aches, carpal tunnelNo published dataGrowth hormone trials; tesamorelin label
Higher blood sugar, lower insulin sensitivityNo published dataMK-677 trial; ghrelin infusion study
Headache, dizziness, feeling hotNo published dataMacimorelin label (single oral test dose)
Injection-site redness or itchingNo published dataTesamorelin label (another injected peptide)
Immune reactions from impuritiesNo published dataFDA safety listing for compounded ipamorelin
Serious adverse events, including deathReported with intravenous use, per the FDAFDA safety listing
Possible ipamorelin side effects and the evidence behind each, cited below.

Bottom line: most of the list of possible ipamorelin side effects is inference from related drugs, and for long-term use nobody has measured them at all.

Clinical Studies

Ipamorelin Side Effects in Clinical Studies

Ipamorelin side effects in clinical studies come from two small human studies, both of intravenous ipamorelin, and neither tested the uses it is marketed for today.

The larger was a phase 2, multicenter, double-blind, placebo-controlled trial in adults recovering from small or large bowel resection, who received intravenous infusions of ipamorelin or placebo twice daily for up to seven days. Of 117 patients enrolled, 114 made up the safety population. Any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group, rates that mostly reflect the surgery. It also missed its goal: time to a tolerated solid meal did not differ significantly from placebo.

The other was a 1999 dose-escalation study in healthy men, eight at each of five infusion rates given over 15 minutes. It measured a half-life of about two hours and a single growth hormone pulse peaking at about 0.67 hours, and was not designed to describe side effects.

Neither study describes subcutaneous injections taken at home for months, which is how compounded ipamorelin is prescribed, and hospital IV data should not be read across to that use.

The clinical record on ipamorelin side effects is short-term, intravenous and small.

Selectivity

Ipamorelin Side Effects Compared to GHRP-2 and GHRP-6

Ipamorelin side effects compared to GHRP-2 and GHRP-6 look milder on the hormone side, but that comparison was made in animals, not people.

In the 1998 paper that introduced ipamorelin, researchers tested it in rat cells, rats and swine. In swine, GHRP-6 and GHRP-2 raised ACTH and cortisol, while ipamorelin did not raise them beyond the levels seen after GHRH, even at doses more than 200-fold higher than the dose needed for growth hormone release. None of the peptides tested changed prolactin, FSH, LH or TSH.

That animal finding is why ipamorelin is called selective, and no published human trial has confirmed it. A related oral ghrelin mimetic, MK-677, raised cortisol by an average of 47 nmol/L over a year in a trial in 65 healthy adults aged 60 to 81, so the question deserves testing in people.

Compared with GHRP-2 and GHRP-6, ipamorelin's cleaner hormone profile is an animal result that still needs confirmation in people.

Water Retention

Does Ipamorelin Cause Water Retention?

Ipamorelin may cause water retention, because raising growth hormone tends to make the body hold fluid, but no study has measured water retention in people taking ipamorelin itself.

The signal comes from drugs that raise growth hormone. A systematic review of growth hormone trials in healthy older adults found more soft tissue swelling, joint pain, carpal tunnel syndrome and male breast enlargement (gynecomastia) with treatment. The label for tesamorelin (Egrifta SV), an FDA-approved peptide acting on a different receptor, warns that fluid retention may occur and may include edema, joint pain and carpal tunnel syndrome.

Ipamorelin produces shorter growth hormone pulses than injected growth hormone, so the effect may be smaller, which is plausible but not demonstrated.

Water retention with ipamorelin is a borrowed class warning, and swelling, tingling hands or new joint pain are reasons to call your prescriber.

Hunger and Glucose

Ipamorelin Side Effects: Hunger and Blood Sugar

Ipamorelin side effects on hunger and blood sugar are expected from its target, because ipamorelin acts on the ghrelin receptor, the receptor the body's hunger hormone uses.

Drugs that share that receptor show both effects. In the MK-677 trial, over the first year, an increase in appetite that subsided over a few months was the most frequent side effect, fasting blood glucose rose by an average of 5 mg/dL and insulin sensitivity decreased. The label for macimorelin (Macrilen), an FDA-approved oral ghrelin-receptor agonist used as a diagnostic test, lists hunger among its most common adverse reactions after a single dose. In two phase 3 anamorelin trials in lung cancer cachexia, high blood sugar was the most common severe adverse event, in 1% or fewer of patients.

Ghrelin itself raised glucose and lowered insulin in 11 healthy volunteers, while the synthetic peptide hexarelin did not, and ipamorelin's own effect has not been reported.

Hunger and higher blood sugar are the most predictable ipamorelin side effects from its mechanism, and they matter most for people with prediabetes or diabetes.

Headaches

Ipamorelin Side Effects: Headaches, Flushing and Injection-Site Reactions

Ipamorelin side effects such as headaches, flushing and injection-site reactions are listed by many clinics, but no published data for subcutaneous ipamorelin show how often they occur.

The closest labeled evidence is indirect. The macimorelin label lists headache, dizziness, fatigue, nausea, feeling hot and excessive sweating among its most common reactions after one oral dose. The tesamorelin label lists injection-site redness and itching among its most common reactions and warns that hypersensitivity reactions have occurred in clinical trials.

Compounded injections add a separate risk. The FDA says compounded ipamorelin may pose a risk of immune reactions for some routes because of aggregation or peptide-related impurities.

Hives, facial swelling or trouble breathing after an injection need emergency care. Headaches, flushing and site reactions are plausible ipamorelin side effects whose frequency with subcutaneous use is unknown.

Long-Term

What Are the Long-Term Side Effects of Ipamorelin?

The long-term side effects of ipamorelin are unknown, because no published study has followed people taking it for longer than seven days.

Three concerns come from related drugs. The first is cell growth: the tesamorelin label says preexisting cancer should be inactive and treated before starting, and that the effects of prolonged IGF-1 elevation are unknown. The second is heart failure: a phase IIb trial of MK-677 in 123 older adults recovering from hip fracture stopped early over a congestive heart failure signal. The third is heart rhythm: the macimorelin label warns that it can prolong the QT interval.

None of those findings was made with ipamorelin; they are reasons to monitor, not proof of harm.

Long-term ipamorelin side effects have not been studied, so any long course is an unmeasured exposure that needs labs and follow-up.

Men and Women

Ipamorelin Side Effects in Men and Women

Ipamorelin side effects in men and women have not been compared, because no published human study reported side effects by sex.

The 1999 study enrolled only men, and the surgery trial's published summary did not report adverse events by sex. Gynecomastia is a growth hormone class concern for men, and there are no human safety data in pregnancy or breastfeeding.

Ipamorelin side effects for men and for women share the same unknowns, with breast changes a specific thing for men to report and pregnancy a specific reason for women to avoid it.

Safety

Is Ipamorelin Safe?

Ipamorelin has not been shown to be safe for long-term use, and the FDA has flagged compounded ipamorelin as a bulk substance that may present significant safety risks.

The FDA's list of bulk drug substances that may present significant safety risks (current as of April 22, 2026) places ipamorelin acetate in Category 2 under the 503B interim policy for outsourcing facilities, added September 29, 2023. It also appears among nominations withdrawn by their nominators, with the note that it stays in the table "because it is in category 2 under the 503B interim policy." The FDA writes that "a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility," and that it "has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration."

The FDA entry does not name the study, and the published phase 2 IV trial reported overall adverse events no more often than placebo, so an honest safety picture includes both.

Based on the class warnings, poor candidates include anyone with active cancer, pregnancy, poorly controlled diabetes or heart failure. For athletes, the World Anti-Doping Agency's 2026 Prohibited List names ipamorelin under S2.2.4, growth hormone releasing factors, which are prohibited at all times, in and out of competition.

Ipamorelin's safety is unproven rather than disproven, and the FDA's Category 2 listing is the clearest official statement of the risk.

FDA Status

Is Ipamorelin FDA Approved?

Ipamorelin is not FDA approved for any use, and compounded ipamorelin is not FDA approved either.

No ipamorelin product has been through FDA review for safety and effectiveness. The FDA's compounding questions and answers state that compounded drugs are not FDA-approved, which means the FDA does not verify their safety, effectiveness or quality before they are marketed. Its clinical development targeted gut motility after surgery and stopped short of approval.

Ipamorelin's FDA status is simple: never approved, and listed by the FDA among bulk substances that may present significant safety risks.

Our Approach

Ipamorelin at Protocol Health

Ipamorelin at Protocol Health is prescribed only after a physician evaluation of these risks, your history and baseline labs. Protocol Health sells compounded ipamorelin and the CJC-1295 and ipamorelin combination, so we have a commercial interest in this decision, and a consultation can end with a recommendation not to start.

Our peptide therapy page explains the other options, and our guides to what ipamorelin is and ipamorelin vs tesamorelin cover the mechanism and tesamorelin, which is FDA-approved only for excess abdominal fat in HIV-associated lipodystrophy.

In-person care is at our Scarsdale, NY clinic, and telehealth visits are available in New York, New Jersey, Connecticut, Florida and California. Start with our short assessment to see whether a consultation fits.

Ipamorelin at Protocol Health means the risks are discussed first and monitored throughout, with a physician deciding whether it fits at all.

FAQ

Frequently Asked Questions

Does ipamorelin make you hungry?

It might. Ipamorelin acts on the ghrelin receptor, the hunger hormone's receptor, and related drugs such as MK-677 and macimorelin list increased appetite or hunger as common side effects. How often it happens with ipamorelin has not been measured.

Can ipamorelin cause headaches?

Possibly. Headache is among the most common reactions to macimorelin, an approved drug that acts on the same receptor, but no published study has reported headache rates for subcutaneous ipamorelin.

Does ipamorelin affect the heart?

No study has tested ipamorelin's effect on the heart. Related drugs raise concerns: an MK-677 trial stopped early over a heart failure signal, and the macimorelin label warns of QT prolongation.

Is ipamorelin banned in sports?

Yes. The World Anti-Doping Agency's 2026 Prohibited List names ipamorelin under S2.2.4, growth hormone releasing factors, which are prohibited at all times.

What should I do if I get side effects from ipamorelin?

Contact the clinician who prescribed it. Seek emergency care for hives, swelling of the face or throat, or trouble breathing after an injection.

Explore

Related at Protocol Health

Talk to a physician about ipamorelin

Medical disclaimer

This article is for education only and is not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, stopping, or changing any medication.

Important safety information

References

  1. phase 2, multicenter, double-blind, placebo-controlled trial. PubMed. https://pubmed.ncbi.nlm.nih.gov/25331030/
  2. 1999 dose-escalation study. PubMed. https://pubmed.ncbi.nlm.nih.gov/10496658/
  3. 1998 paper that introduced ipamorelin. PubMed. https://pubmed.ncbi.nlm.nih.gov/9849822/
  4. a trial in 65 healthy adults aged 60 to 81. PubMed. https://pubmed.ncbi.nlm.nih.gov/18981485/
  5. systematic review of growth hormone trials in healthy older adults. PubMed. https://pubmed.ncbi.nlm.nih.gov/17227934/
  6. label for tesamorelin (Egrifta SV). National Institutes of Health. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
  7. label for macimorelin (Macrilen). National Institutes of Health. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6034c9b8-5a36-4961-a5dd-11ebf7bdab78
  8. two phase 3 anamorelin trials. PubMed. https://pubmed.ncbi.nlm.nih.gov/26906526/
  9. 11 healthy volunteers. PubMed. https://pubmed.ncbi.nlm.nih.gov/11600590/
  10. FDA. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Show all 13 references
  1. phase IIb trial of MK-677 in 123 older adults recovering from hip fracture. PubMed. https://pubmed.ncbi.nlm.nih.gov/21067829/
  2. World Anti-Doping Agency's 2026 Prohibited List. wada-ama.org. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  3. FDA's compounding questions and answers. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Why trust our physicians

Every article is reviewed by a licensed physician on our medical team and is kept current by our editorial team. Read our editorial policy and our medical review process.

Medically reviewed by
Richard Dentico, MD on
Written by
Protocol Health Editorial Team
First published
Last updated

See an error? Email care@protocolhealthmd.com and we will review it.

More on Growth Hormone Peptides

All Peptides articles →